Cancer Family
Secondary Malignant Neoplasm
CI-CAN-00000346SMNExplore in graph →
4,270 active trials56 approved drugs532 evidence items
- NCIt
- C4968
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000346SMNExplore in graph →
Clinical trials
14,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,961)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03111901 | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer(UVA-AM-002) | withdrawn | Phase 1 / Phase 2 | 0 | William Grosh, MDOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT03057509 | A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors | withdrawn | Phase 1 | 0 | Massachusetts General HospitalOTHER | 1 | Jun 21, 2019 | clinicaltrials |
| NCT03652233 | Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Jun 20, 2019 | clinicaltrials |
| NCT03697239 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Hitendra PatelOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT03908333 | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Medical College of WisconsinOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT03114280 | Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)(PICH) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Antoine LacassagneOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT02867332 | PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma. | withdrawn | Phase 1 | 0 | Peking UniversityOTHER | 0 | Mar 6, 2019 | clinicaltrials |
| NCT02050009 | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 1 | 0 | Fox Chase Cancer CenterOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT03045393 | Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC(IMGN853) | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01956864 | Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer | withdrawn | Phase 1 | 0 | Johns Hopkins UniversityOTHER | 1 | Feb 1, 2018 | clinicaltrials |
| NCT02993991 | Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity(PRIMED-001) | withdrawn | Phase 1 | 0 | University Health Network, TorontoOTHER | 1 | Dec 29, 2017 | clinicaltrials |
| NCT03307941 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA(ARTEMIS-Eso) | withdrawn | Phase 1 / Phase 2 | 0 | Jules Bordet InstituteOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT02298595 | Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | Julie E. Bauman, MD, MPHOTHER | 0 | Nov 13, 2017 | clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |
| NCT02211027 | Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA | withdrawn | Phase 1 | 0 | Robert FerrisOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT02227914 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | AmgenINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT02997956 | Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE) | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 24, 2017 | clinicaltrials |
| NCT03117855 | Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT01335074 | Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | withdrawn | Phase 1 / Phase 2 | 0 | Philipps University MarburgOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT02528877 | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Sep 14, 2016 | clinicaltrials |
| NCT02627430 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 26, 2016 | clinicaltrials |
| NCT00627835 | Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN) | withdrawn | Phase 1 | 0 | British Columbia Cancer AgencyOTHER | 1 | Jul 20, 2016 | clinicaltrials |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 20, 2016 | clinicaltrials |
| NCT02143622 | Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 21, 2016 | clinicaltrials |
| NCT02536495 | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Erin BertinoOTHER | 0 | Oct 30, 2015 | clinicaltrials |
| NCT01586182 | Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 4, 2015 | clinicaltrials |
| NCT01801163 | A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC) | withdrawn | Phase 1 | 0 | Indiana UniversityOTHER | 1 | Apr 16, 2015 | clinicaltrials |
| NCT02059967 | Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC | withdrawn | Phase 1 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Mar 19, 2015 | clinicaltrials |
| NCT01465815 | Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN) | withdrawn | Phase 1 / Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 19, 2014 | clinicaltrials |
| NCT01741597 | Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | May 30, 2014 | clinicaltrials |
| NCT01728480 | Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Dec 11, 2013 | clinicaltrials |
| NCT01618253 | Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 1 | Sep 5, 2013 | clinicaltrials |
| NCT01219907 | Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer | withdrawn | Phase 1 | 0 | University of WashingtonOTHER | 1 | May 17, 2013 | clinicaltrials |
| NCT01491139 | Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck(ORCA) | withdrawn | Phase 1 | 0 | University College, LondonOTHER | 0 | May 30, 2012 | clinicaltrials |
| NCT01441388 | A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. | withdrawn | Phase 1 | 0 | PfizerINDUSTRY | 0 | Dec 20, 2011 | clinicaltrials |
| NCT00937300 | T-cell Based Immunotherapy for Head and Neck Cancer | withdrawn | Phase 1 | 0 | Inge Marie SvaneOTHER | 1 | Nov 23, 2011 | clinicaltrials |
| NCT00415155 | A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 60 | Eli Lilly and CompanyINDUSTRY | 4 | Aug 29, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Jul 12, 2019source: clinicaltrials